Keywords: AstraZeneca, First-quarter 2010
AstraZeneca posts 29% rise in 1st-qtr 2010 profits, but warns of tougher times as key patents expire
Article | 30 April 2010
Anglo-Swedish drug major AstraZeneca reported that first-quarter profit rose 29 % to $2.9 billion, and revenues were up 11% (+7% at constant exchange rates), reaching $8.58 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
